Finerenone Clinical Trials (2026): 75 Studies for Chronic Kidney Disease & Type 2 Diabetes Mellitus
Hipa.ai Research · Source: ClinicalTrials.gov / AACT
Synced daily from ClinicalTrials.gov via AACT. Last sync: .
75 Finerenone clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 39 indications (including Chronic Kidney Disease & Type 2 Diabetes Mellitus) and 341,809 total planned enrollment. 19 Phase 3 Finerenone trials and 9 Phase 2, 22 Phase 4 are listed. 38 Finerenone clinical trials are actively recruiting at 102 U.S. sites across 33 states. Most recent activity: NCT02378805 (Mar 2036).
Where to Participate: All Finerenone Trial Sites in the U.S. (102 sites across 33 states)
Every actively recruiting Finerenonetrial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.
| State | Facility | City | Trial | Map |
|---|---|---|---|---|
| AL | Birmingham, AL Investigative Site 10012 | Birmingham35205 | NCT06008197 | Map |
| AL | CON-10004 Fairhope, AL Investigational Site | Fairhope36532 | NCT06024746 | Map |
| AL | Fairhope, AL Investigative Site 10004 | Fairhope36532 | NCT06008197 | Map |
| AL | FIN-10004 Fairhope, AL Investigational Site | Fairhope36532 | NCT06033950 | Map |
| AL | Huntsville, AL Investigative Site 10026 | Huntsville35801 | NCT06008197 | Map |
| AZ | Glendale, AZ Investigative Site 10096 | Glendale85304 | NCT06008197 | Map |
| AZ | Scottsdale, AZ Investigative Site 10003 | Scottsdale85258 | NCT06008197 | Map |
| CA | Chula Vista, CA Investigative Site 10111 | Chula Vista91911 | NCT06008197 | Map |
| CA | CON-10075 El Centro, CA Investigational Site | El Centro92243 | NCT06024746 | Map |
| CA | Huntington Beach, CA Investigative Site 10031 | Huntington Beach92648 | NCT06008197 | Map |
| CA | Los Angeles, CA Investigative Site 10089 | Los Angeles90073 | NCT06008197 | Map |
| CA | Lucille Packard Children's Hospital Stanford - Pediatric Nephrology | Palo Alto94304 | NCT05457283 | Map |
| CA | Lucille Packard Children's Hospital Stanford - Pediatric Nephrology | Palo Alto94304 | NCT05196035 | Map |
| CA | CON-10024 Sacramento, CA Investigational Site | Sacramento95816 | NCT06024746 | Map |
| CA | Sacramento, CA Investigative Site 10024 | Sacramento95816 | NCT06008197 | Map |
| CA | FIN-10075 San Diego, CA Investigational Site | San Diego92243 | NCT06033950 | Map |
| CA | UC San Diego - Altman Clinical and Translational Research Institute (ACTRI) - Linda Vista Clinic | San Diego92023 | NCT05196035 | Map |
| CA | San Francisco, CA Investigative Site 10023 | San Francisco94118 | NCT06008197 | Map |
| CA | Tarzana, CA Investigative Site 10409 | Tarzana91356 | NCT06008197 | Map |
| CA | Van Nuys, CA Investigative Site 10109 | Van Nuys91405 | NCT06008197 | Map |
| CA | West Hills, CA Investigative Site 10013 | West Hills91307 | NCT06008197 | Map |
| CO | Aurora, CO Investigative Site 10001 | Aurora80045 | NCT06008197 | Map |
| CO | Denver, CO Investigative Site 10005 | Denver80204 | NCT06008197 | Map |
| FL | Bradenton, FL Investigative Site 10125 | Bradenton34209 | NCT06008197 | Map |
| FL | Brooksville, FL Investigative Site 10077 | Brooksville34613 | NCT06008197 | Map |
| FL | Fort Lauderdale, FL Investigative Site 10114 | Fort Lauderdale33308 | NCT06008197 | Map |
| FL | Fort Myers, FL Investigative Site 10076 | Fort Myers33919 | NCT06008197 | Map |
| FL | Hialeah, FL Investigative Site 10104 | Hialeah33012 | NCT06008197 | Map |
| FL | Memorial Transplant Institute - Pediatric Nephrology | Hollywood33021 | NCT05196035 | Map |
| FL | Jacksonville, FL Investigative Site 10028 | Jacksonville32209 | NCT06008197 | Map |
| FL | Miami, FL Investigative Site 10040 | Miami33173 | NCT06008197 | Map |
| FL | Miami, FL Investigative Site 10105 | Miami33135 | NCT06008197 | Map |
| GA | Atlanta, GA Investigative Site 10022 | Atlanta30303 | NCT06008197 | Map |
| GA | CON-10022 Atlanta, GA Investigational Site | Atlanta30303 | NCT06024746 | Map |
| GA | Duluth, GA Investigative Site 10083 | Duluth30096 | NCT06008197 | Map |
| ID | Boise, Idaho Investigative Site 10073 | Boise83712 | NCT06008197 | Map |
| IL | Chicago, IL Investigative Site 10062 | Chicago60612 | NCT06008197 | Map |
| IL | Glenview, IL Investigative Site 10021 | Glenview60026 | NCT06008197 | Map |
| IL | Naperville, IL Investigative Site 10025 | Naperville60540 | NCT06008197 | Map |
| IL | Peoria, IL Investigative Site 10010 | Peoria61614 | NCT06008197 | Map |
| IL | Peoria, IL Investigative Site 10019 | Peoria61603 | NCT06008197 | Map |
| IN | Indianapolis, IN Investigative Site 10008 | Indianapolis46260 | NCT06008197 | Map |
| IN | Indianapolis, IN Investigative Site 10074 | Indianapolis46237 | NCT06008197 | Map |
| IN | Merrillville, IN Investigative Site 10064 | Merrillville46410 | NCT06008197 | Map |
| KS | Kansas City, KS Investigative Site 10060 | Kansas City66103 | NCT06008197 | Map |
| KY | Lexington, KY Investigative Site 10080 | Lexington40503 | NCT06008197 | Map |
| KY | Lexington, KY Investigative Site 10118 | Lexington40536 | NCT06008197 | Map |
| KY | Louisville, KY Investigative Site 10006 | Louisville40202 | NCT06008197 | Map |
| KY | Paducah, KY Investigative Site 10079 | Paducah42003 | NCT06008197 | Map |
| LA | Baton Rouge, LA Investigative Site 10030 | Baton Rouge70808 | NCT06008197 | Map |
| LA | CON-10030 Baton Rouge, LA Investigational Site | Baton Rouge70808 | NCT06024746 | Map |
| LA | Hammond, LA Investigative Site 10106 | Hammond70403 | NCT06008197 | Map |
| LA | West Monroe, LA Investigative Site 10090 | West Monroe71291 | NCT06008197 | Map |
| MD | Baltimore, MD Investigative Site 10101 | Baltimore21287 | NCT06008197 | Map |
| MD | The Charlotte R. Bloomberg Children's Center Building - Nephrology | Baltimore21287 | NCT05457283 | Map |
| MD | The Charlotte R. Bloomberg Children's Center Building - Nephrology | Baltimore21287 | NCT05196035 | Map |
| MD | Bowie, MD Investigative Site 10020 | Bowie20715 | NCT06008197 | Map |
| MA | Boston, MA Investigative Stie 10087 | Boston02114 | NCT06008197 | Map |
| MN | Minneapolis, MN Investigative Site 10035 | Minneapolis55417 | NCT06008197 | Map |
| MN | Minneapolis, MN Investigative Site 10091 | Minneapolis55407-1139 | NCT06008197 | Map |
| MO | Children's Mercy Hospital Kansas City - Nephrology | Kansas City64108 | NCT05196035 | Map |
| MO | CON-10002 Kansas City, MO Investigative Site | Kansas City64111 | NCT06024746 | Map |
| MO | FIN-10002 Kansas City, MO Investigational Site | Kansas City64111 | NCT06033950 | Map |
| MO | Kansas City, MO Investigative Site 10002 | Kansas City64111 | NCT06008197 | Map |
| NE | Omaha, NE Investigative Site 10018 | Omaha68105 | NCT06008197 | Map |
| NJ | Camden, NJ Investigative Site 10033 | Camden08103 | NCT06008197 | Map |
| NY | Roslyn, NY Investigative Site 10058 | Roslyn11576 | NCT06008197 | Map |
| NY | Stony Brook, NY Investigative Site 10017 | Stony Brook11794-8171 | NCT06008197 | Map |
| NC | UNC Eastowne Kidney Transplant Clinic | Chapel Hill27514 | NCT06059664 | Map |
| OH | Akron, OH Investigative Site 10081 | Akron44304 | NCT06008197 | Map |
| OH | Centerville, OH Investigative Site 10119 | Centerville45459 | NCT06008197 | Map |
| OH | Cincinnati Children's Hospital Medical Center | Division of Nephrology and Hypertension | Cincinnati45229 | NCT05196035 | Map |
| OH | Cincinnati, OH Investigative Site 10088 | Cincinnati45220 | NCT06008197 | Map |
| OH | Cleveland Clinic | Pediatric Nephrology | Cleveland14013 | NCT05457283 | Map |
| OH | Cleveland Clinic | Pediatric Nephrology | Cleveland14013 | NCT05196035 | Map |
| OK | Bartlesville, OK Investigative Site 10095 | Bartlesville74006 | NCT06008197 | Map |
| OR | OHSU Doernbecher Children's Hospital - Neurology | Portland97239 | NCT05196035 | Map |
| PA | Philadelphia, PA Investigative Site 10068 | Philadelphia19107 | NCT06008197 | Map |
| PA | Pittsburg, PA Investigative Site 1044 | Pittsburgh15212 | NCT06008197 | Map |
| RI | Providence, RI Investigative Site 10050 | Providence02908 | NCT06008197 | Map |
| SC | Charleston, SC Investigative Site 10056 | Charleston29425 | NCT06008197 | Map |
| TN | Germantown, TN Investigative Site 10063 | Germantown38138 | NCT06008197 | Map |
| TN | Memphis, TN Investigative Site 10059 | Memphis38105 | NCT06008197 | Map |
| TN | Nashville, TN Investigative Site 10071 | Nashville37203 | NCT06008197 | Map |
| TX | Amarillo, TX Investigative Site 10045 | Amarillo79106 | NCT06008197 | Map |
| TX | CON-10045 Amarillo, TX Investigational Site | Amarillo79106 | NCT06024746 | Map |
| TX | Austin, TX Investigative Site 10015 | Austin78705 | NCT06008197 | Map |
| TX | CON-10015 Austin, TX Investigational Site | Austin78705 | NCT06024746 | Map |
| TX | FIN-10015 Austin, TX Investigational Site | Austin78705 | NCT06033950 | Map |
| TX | Dallas, TX Investigative Site 10042 | Dallas75216 | NCT06008197 | Map |
| TX | Houston, TX Investigative Site 10085 | Houston77030 | NCT06008197 | Map |
| TX | Plano, TX Investigative Site 10014 | Plano75093 | NCT06008197 | Map |
| UT | Eccles Primary Children's Outpatient Services - Nephrology | Salt Lake City84113 | NCT05457283 | Map |
| UT | Eccles Primary Children's Outpatient Services - Nephrology | Salt Lake City84113 | NCT05196035 | Map |
| VT | Burlington, VT Investigative Site 10053 | Burlington05401 | NCT06008197 | Map |
| VA | Norfolk, VA Investigative Site 10009 | Norfolk23507 | NCT06008197 | Map |
| VA | Richmond, VA Investigative Site 10067 | Richmond23249 | NCT06008197 | Map |
| VA | Richmond, VA Investigative Site 10069 | Richmond23225 | NCT06008197 | Map |
| VA | Salem, VA Investigative Site 10048 | Salem24153 | NCT06008197 | Map |
| VA | Sarfez Pharmaceuticals, Inc. | Vienna22182 | NCT07223502 | Map |
| WA | Seattle Children's Hospital - Nephrology | Seattle98105 | NCT05196035 | Map |
| WI | Milwaukee, WI Investigative Site 10061 | Milwaukee53226 | NCT06008197 | Map |
Finerenone clinical trials at a glance: phase × recruitment status
| Phase | recruiting | active not recruiting | enrolling by invitation | completed | terminated | not yet recruiting | unknown | Total |
|---|---|---|---|---|---|---|---|---|
| P1 | 6 | 6 | ||||||
| P2 | 2 | 5 | 2 | 9 | ||||
| P3 | 10 | 1 | 6 | 2 | 19 | |||
| P4 | 7 | 1 | 2 | 4 | 6 | 2 | 22 | |
| N/A | 6 | 3 | 8 | 2 | 19 |
Recruiting Finerenone clinical trials (38)
Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).
| NCT ID | Title | Phase | Indication | Enrollment | Started |
|---|---|---|---|---|---|
| NCT02378805 | Alport-XXLAlport Therapy Registry - European Initiative Towards Delaying Renal Failure in Alport Syndrome | — | Alport Syndrome | 800 | Jul 1995 |
| NCT07270367 | FINE-MECHFinerenone and Cardiac Remodeling | P3 | Heart Failure | 156 | Dec 2025 |
| NCT07192952 | FIORELLOA Study to Learn More About How Safe Finerenone is, When it is Taken for a Longer Time With Standard Treatment, in Children and Young Adults With Heart Failure and Left Ventricular Systolic Dysfunction | P3 | Left Ventricular Systolic Dysfunction | 117 | Jun 2026 |
| NCT07442448 | FINE-REMODELInvestigation on the Impact of Finerenone on Myocardial Remodeling in Patients With Diabetic Kidney Disease and Heart Failure | P4 | Heart Failure and Preserved Ejection Fraction | 40 | Apr 2026 |
| NCT07188805 | FIOREA Study to Learn More About How Well Finerenone Works, How Safe it is, and How it Moves Into, Through, and Out of the Body Compared to Placebo When Taken With Standard Treatment in Children With Heart Failure and Left Ventricular Systolic Dysfunction | P3 | Left Ventricular Systolic Dysfunction | 111 | Nov 2025 |
| NCT06082063 | Steno1Multifactorial Intervention to Reduce Cardiovascular Disease in Type 1 Diabetes | P3 | Cardiovascular Diseases | 2,000 | Jul 2024 |
| NCT07554469 | FINEXPLORERAn Observational Study, Called FINEXPLORER, to Learn More About How Well Finerenone Works in Adults in Spain With Chronic Kidney Disease (CKD) Linked to Type 2 Diabetes, by Looking at Changes in a CKD Risk Score | — | Chronic Kidney Disease | 500 | May 2026 |
| NCT07547878 | RAPID-CKDRapid and Simultaneous Initiation of Four Guideline-Directed CKD Therapies (RAPID-CKD) | P4 | Chronic Kidney Disease | 64 | Apr 2026 |
| NCT06058585 | CAPTIVATEThe Chronic Kidney Disease Adaptive Platform Trial Investigating Various Agents for Therapeutic Effect | P3 | Chronic Kidney Diseases | 1,000 | Sep 2024 |
| NCT05457283 | FIONA OLEA Study to Learn More About How Safe the Study Treatment Finerenone is in Long-term Use When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker Over 18 Months of Use in Children and Young Adults From 1 to 18 Years of Age With Chronic Kidney Disease and Proteinuria | P3 | Chronic Kidney Disease | 100 | Nov 2022 |
| NCT07397650 | FACILITATE-HFEfficacy and Safety With Early Treatment of Finerenone in Hospitalized Patients With Heart Failure | P4 | Acute Heart Failure | 550 | Feb 2026 |
| NCT07239570 | CKD-bioMatchA Biomarker-targeted Clinical Trial to Optimize Treatment for Patients With Chronic Kidney Disease | P4 | Chronic Kidney Disease(CKD) | 125 | Jun 2025 |
| NCT07315191 | FICHSPNFinerenone Therapy for Pediatric HSPN With Mild Proteinuria | P4 | Henoch Schönlein Purpura Nephritis | 116 | Jun 2025 |
| NCT07026539 | FineCaReEffect of Treatment With Finerenone on Cardio-Renal Target Organ Damage in Patients With Type 2 Diabetes. | P4 | Type 2 Diabetes Mellitus (T2DM) | 80 | Oct 2024 |
| NCT06033950 | FINALITY-HFA Study to Evaluate Finerenone on Clinical Efficacy and Safety in Patients with Heart Failure Who Are Intolerant or Not Eligible for Treatment with Steroidal Mineralocorticoid Receptor Antagonists | P3 | Heart Failure | 2,600 | Aug 2024 |
| NCT06906081 | FibroCANFinerenone Treatment for Diabetic Cardiovascular Autonomic Neuropathy: the FibroCAN Study | P2 | Cardiovascular Autonomic Neuropathy | 100 | May 2025 |
| NCT07232537 | An Observational Study Called FINE-REAL Korea to Learn More About the Use of the Drug Finerenone in People With Chronic Kidney Disease and Type 2 Diabetes in a Routine Medical Care Setting in South Korea | — | Chronic Kidney Disease | 500 | Nov 2025 |
| NCT07181135 | FINE-STARTFINE-START: Efficacy and Safety of Finerenone in Patients With Chronic Kidney Disease Not Using Renin-angiotensin-system Inhibitors | P3 | Chronic Kidney Disease | 180 | Mar 2026 |
| NCT06059664 | The EFfect of FinErenone in Kidney TransplantiOn Recipients: The EFFEKTOR Study | P2 | Kidney Transplant; Complications | 100 | Apr 2024 |
| NCT06008197 | REDEFINE-HFA Study to Determine the Efficacy and Safety of Finerenone on Morbidity and Mortality Among Hospitalized Heart Failure Patients | P3 | Heart Failure | 5,200 | Jan 2024 |
| NCT07379840 | A Study to Learn More About How Safe Finerenone is and How Well it Works in Adults With Chronic Heart Failure in South Korea | — | Chronic Heart Failure | 300 | Dec 2025 |
| NCT07155694 | Role of Finerenone in African American Veterans With Diabetic Kidney Disease | P4 | Diabetic Kidney Disease | 30 | Sep 2025 |
| NCT05196035 | FIONAA Study to Learn More About How Well the Study Treatment Finerenone Works, How Safe it is, How it Moves Into, Through, and Out of the Body, and the Effects it Has on the Body When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker in Children With Chronic Kidney Disease and Proteinuria | P3 | Chronic Kidney Disease | 219 | Mar 2022 |
| NCT07537088 | Efficacy and Safety of Triple Therapy With Dulaglutide, SGLT2 Inhibitors, and Finerenone in Chinese Adults With Type 2 Diabetes and Chronic Kidney Disease | P4 | T2DM (Type 2 Diabetes Mellitus) | 468 | May 2026 |
| NCT06954090 | SIGNALUrinary Proteomics to Guide Early Intervention to Prevent Complications in Type 2 Diabetes - a Feasibility Study | P4 | Type 2 DM | 50 | Nov 2025 |
| NCT07235891 | Retinal Protective Effects of Novel Finerenone in Patients With Chronic Kidney Disease | P4 | Retinal Nerve Fiber Layer Thickness | 40 | Nov 2025 |
| NCT06727409 | RAiSiNUse of Clinical-trials and Simulation Models to Estimate Cost-effectiveness of Non-steroidal Mineralocorticoid Antagonists, RASi and SGLT2i as Triple Therapy With Type 2 Diabetes and Chronic Kidney Disease | P4 | Patients With Type 2 Diabetes | 82 | Dec 2024 |
| NCT06838416 | KSD-01Evaluation of the Effect of Finerenone on Renal Function in Patients With Type 2 Diabetes and Chronic Kidney Disease | — | Type 2 Diabetes Mellitus | 300 | Nov 2023 |
| NCT07523867 | SAFE-KSpironolactone Alternate Dosing vs Finerenone in Elevated Potassium - K Safety Study | P4 | Heart Failure | 60 | Apr 2026 |
| NCT07223502 | NEPHRONA Study Comparing the Clinical Benefit of Finerenone Versus a Fixed Dose Combination (FDC) of Extended-Release Torsemide and Spironolactone in Patients With Hypertension and Chronic Kidney Disease | P3 | Hypertension (HTN) | 30 | Dec 2025 |
| NCT06573411 | Efficacy and Safety of Finerenone in Patients With Primary Membranous Nephropathy | P4 | Primary Membranous Nephropathy | 116 | Sep 2024 |
| NCT06580288 | FIGHTEffect of Finerenone in IgA Nephropathy | P3 | IgA Nephropathy | 120 | Oct 2024 |
| NCT06278207 | FINERODAn Observational Study Called FINEROD to Learn More About the Use of the Treatment Finerenone Including How Safe it is and How Well it Works Under Real-world Conditions | — | Chronic Kidney Disease | 50,000 | May 2024 |
| NCT06024746 | CONFIRMATIONA Study to Determine the Efficacy and Safety of Finerenone and SGLT2i in Combination in Hospitalized Patients with Heart Failure (CONFIRMATION-HF) | P3 | Heart Failure | 1,500 | Jul 2024 |
| NCT07351864 | FIN-SGLT2-HFFinerenone Plus SGLT2 Inhibitors in Heart Failure | P4 | Heart Failure | 60 | Jan 2026 |
| NCT07326631 | Finerenone for Cardiorenal Protection in Diabetic CKD: Impact on Renal Function Decline and Heart Failure | N/A | Diabetic Kidney Disease (DKD) | 120 | Jan 2026 |
| NCT06457074 | FAIRYFinerenone for Patients With Primary Aldosteronism (FAIRY) | P4 | Primary Aldosteronism | 306 | Jun 2024 |
| NCT07056595 | Finerenone in Patients With IgA-nephropathy: Prospective Interventional Trial | N/A | IgA Nephropathy (IgAN) | 30 | May 2025 |
Finerenone clinical trials by indication
Chronic Kidney Disease (18)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07554469 | FINEXPLORER | N/A | not yet recruiting | An Observational Study, Called FINEXPLORER, to Learn More About How Well Finerenone Works in Adults in Spain With Chronic Kidney Disease (CKD) Linked to Type 2 Diabetes, by Looking at Changes in a CKD Risk Score |
| NCT07547878 | RAPID-CKD | P4 | not yet recruiting | Rapid and Simultaneous Initiation of Four Guideline-Directed CKD Therapies (RAPID-CKD) |
| NCT05457283 | FIONA OLE | P3 | recruiting | A Study to Learn More About How Safe the Study Treatment Finerenone is in Long-term Use When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker Over 18 Months of Use in Children and Young Adults From 1 to 18 Years of Age With Chronic Kidney Disease and Proteinuria |
| NCT07232537 | — | N/A | recruiting | An Observational Study Called FINE-REAL Korea to Learn More About the Use of the Drug Finerenone in People With Chronic Kidney Disease and Type 2 Diabetes in a Routine Medical Care Setting in South Korea |
| NCT07181135 | FINE-START | P3 | enrolling by invitation | FINE-START: Efficacy and Safety of Finerenone in Patients With Chronic Kidney Disease Not Using Renin-angiotensin-system Inhibitors |
| NCT05348733 | — | N/A | active not recruiting | A Study Called FINE-REAL to Learn More About the Use of the Drug Finerenone in a Routine Medical Care Setting |
| NCT05196035 | FIONA | P3 | recruiting | A Study to Learn More About How Well the Study Treatment Finerenone Works, How Safe it is, How it Moves Into, Through, and Out of the Body, and the Effects it Has on the Body When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker in Children With Chronic Kidney Disease and Proteinuria |
| NCT06278207 | FINEROD | N/A | recruiting | An Observational Study Called FINEROD to Learn More About the Use of the Treatment Finerenone Including How Safe it is and How Well it Works Under Real-world Conditions |
| + 10 more, see All trials below. | ||||
Heart Failure (8)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07270367 | FINE-MECH | P3 | not yet recruiting | Finerenone and Cardiac Remodeling |
| NCT06033950 | FINALITY-HF | P3 | recruiting | A Study to Evaluate Finerenone on Clinical Efficacy and Safety in Patients with Heart Failure Who Are Intolerant or Not Eligible for Treatment with Steroidal Mineralocorticoid Receptor Antagonists |
| NCT06008197 | REDEFINE-HF | P3 | recruiting | A Study to Determine the Efficacy and Safety of Finerenone on Morbidity and Mortality Among Hospitalized Heart Failure Patients |
| NCT07523867 | SAFE-K | P4 | not yet recruiting | Spironolactone Alternate Dosing vs Finerenone in Elevated Potassium - K Safety Study |
| NCT06024746 | CONFIRMATION | P3 | recruiting | A Study to Determine the Efficacy and Safety of Finerenone and SGLT2i in Combination in Hospitalized Patients with Heart Failure (CONFIRMATION-HF) |
| NCT07351864 | FIN-SGLT2-HF | P4 | not yet recruiting | Finerenone Plus SGLT2 Inhibitors in Heart Failure |
| NCT04435626 | FINEARTS-HF | P3 | completed | Study to Evaluate the Efficacy (Effect on Disease) and Safety of Finerenone in Participants With Heart Failure and Left Ventricular Ejection Fraction (Proportion of Blood Expelled Per Heart Stroke) Greater or Equal to 40% |
| NCT01807221 | ARTS-HF | P2 | completed | Phase IIb Safety and Efficacy Study of Different Oral Doses of BAY94-8862 in Subjects With Worsening Chronic Heart Failure and Left Ventricular Systolic Dysfunction and Either Type 2 Diabetes Mellitus With or Without Chronic Kidney Disease or Chronic Kidney Disease Alone |
Primary Aldosteronism (5)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06457074 | FAIRY | P4 | recruiting | Finerenone for Patients With Primary Aldosteronism (FAIRY) |
| NCT05814770 | — | P4 | unknown | Comparing the Efficacy and Safety of Finerenone and Spironolactone in the Treatment of Primary Aldosteronism |
| NCT06381323 | — | P4 | completed | The Clinical Efficacy and Safety of Finerenone in the Treatment of Primary Aldosteronism |
| NCT06164379 | FAVOR | P4 | unknown | Efficacy and Safety of Finerenone vs. Spironolactone in Patients With Primary Aldosteronism |
| NCT05924620 | — | P4 | completed | Efficacy and Safety of Finerenone in Patients With Primary Aldosteronism |
Diabetic Kidney Disease (3)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07155694 | — | P4 | not yet recruiting | Role of Finerenone in African American Veterans With Diabetic Kidney Disease |
| NCT05897372 | WP3 | P2 | terminated | Feasibility of Aggressive Albuminuria Reduction in Biopsy-Proven Diabetic Nephropathy - a Pilot Study |
| NCT02545049 | FIGARO-DKD | P3 | completed | Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Kidney Disease |
Type 2 Diabetes Mellitus (3)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06838416 | KSD-01 | N/A | recruiting | Evaluation of the Effect of Finerenone on Renal Function in Patients With Type 2 Diabetes and Chronic Kidney Disease |
| NCT05552339 | SMART-Finder | N/A | completed | A Study Called SMART-Finder to Look for People With Increased Amounts of Albumin in the Urine (UACR Level) in a Group of Type 2 Diabetes Mellitus Patients |
| NCT05254002 | CONFIDENCE | P2 | completed | A Study to Learn How Well the Treatment Combination of Finerenone and Empagliflozin Works and How Safe it is Compared to Each Treatment Alone in Adult Participants With Long-term Kidney Disease (Chronic Kidney Disease) and Type 2 Diabetes |
Left Ventricular Systolic Dysfunction (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07192952 | FIORELLO | P3 | recruiting | A Study to Learn More About How Safe Finerenone is, When it is Taken for a Longer Time With Standard Treatment, in Children and Young Adults With Heart Failure and Left Ventricular Systolic Dysfunction |
| NCT07188805 | FIORE | P3 | recruiting | A Study to Learn More About How Well Finerenone Works, How Safe it is, and How it Moves Into, Through, and Out of the Body Compared to Placebo When Taken With Standard Treatment in Children With Heart Failure and Left Ventricular Systolic Dysfunction |
Diabetic Retinopathy (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04795726 | DeFineDR | N/A | completed | A Study That Uses Data From Routine Eye Examinations of Patients Participating in Studies FIDELIO-DKD and FIGARO-DKD to Explore Whether Finerenone Can Delay the Progression of a Diabetes Complication That Affects the Eyes (Diabetic Retinopathy, DR) |
| NCT04477707 | ReFineDR | N/A | completed | A Study That Uses Data From Routine Eye Examinations of Patients Participating in Studies FIDELIO-DKD and FIGARO-DKD to Explore Whether Finerenone Can Delay the Progression of a Diabetes Complication That Affects the Eyes (Diabetic Retinopathy ,DR) |
Pharmacokinetics (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02956109 | — | P1 | completed | Study of Finerenone to Investigate a Paediatric Formulation in Healthy Male Volunteers |
| NCT02957396 | — | P1 | completed | Study of Finerenone to Investigate a Paediatric Formulation in Healthy Male Subjects |
Worsening Chronic Heart Failure (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04881994 | BAY94-8862 | P1 | completed | A Study to Learn How Finerenone (BAY94-8862) Moves Into, Through and Out of the Body, How it Affects the Body, and How Safe it is in Adult Participants With Different Degrees of Reduced Liver Function and in Healthy Participants With Similar Age, Weight and Gender Distribution |
| NCT04908436 | — | P1 | completed | A Study to Learn How BAY94-8862 Moves Into, Through and Out of the Body, How Safe it is and How it Affects the Body in Adult Participants With Reduced Kidney Function and in Healthy Participants With Similar Age, Weight and Gender Distribution |
T2DM (Type 2 Diabetes Mellitus) (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07537088 | — | P4 | not yet recruiting | Efficacy and Safety of Triple Therapy With Dulaglutide, SGLT2 Inhibitors, and Finerenone in Chinese Adults With Type 2 Diabetes and Chronic Kidney Disease |
Heart Failure and Preserved Ejection Fraction (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07442448 | FINE-REMODEL | P4 | enrolling by invitation | Investigation on the Impact of Finerenone on Myocardial Remodeling in Patients With Diabetic Kidney Disease and Heart Failure |
Acute Heart Failure (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07397650 | FACILITATE-HF | P4 | recruiting | Efficacy and Safety With Early Treatment of Finerenone in Hospitalized Patients With Heart Failure |
Diabetic Kidney Disease (DKD) (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07326631 | — | N/A | not yet recruiting | Finerenone for Cardiorenal Protection in Diabetic CKD: Impact on Renal Function Decline and Heart Failure |
Chronic Heart Failure (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07379840 | — | N/A | recruiting | A Study to Learn More About How Safe Finerenone is and How Well it Works in Adults With Chronic Heart Failure in South Korea |
Hypertension (HTN) (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07223502 | NEPHRON | P3 | recruiting | A Study Comparing the Clinical Benefit of Finerenone Versus a Fixed Dose Combination (FDC) of Extended-Release Torsemide and Spironolactone in Patients With Hypertension and Chronic Kidney Disease |
Type 2 DM (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06954090 | SIGNAL | P4 | enrolling by invitation | Urinary Proteomics to Guide Early Intervention to Prevent Complications in Type 2 Diabetes - a Feasibility Study |
Retinal Nerve Fiber Layer Thickness (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07235891 | — | P4 | not yet recruiting | Retinal Protective Effects of Novel Finerenone in Patients With Chronic Kidney Disease |
Chronic Kidney Disease(CKD) (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07239570 | CKD-bioMatch | P4 | recruiting | A Biomarker-targeted Clinical Trial to Optimize Treatment for Patients With Chronic Kidney Disease |
Henoch Schönlein Purpura Nephritis (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07315191 | FICHSPN | P4 | recruiting | Finerenone Therapy for Pediatric HSPN With Mild Proteinuria |
IgA Nephropathy (IgAN) (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07056595 | — | N/A | recruiting | Finerenone in Patients With IgA-nephropathy: Prospective Interventional Trial |
Cardiovascular Autonomic Neuropathy (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06906081 | FibroCAN | P2 | recruiting | Finerenone Treatment for Diabetic Cardiovascular Autonomic Neuropathy: the FibroCAN Study |
Glomerulonephritis (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06835322 | — | P2 | completed | Effect of Finerenone in Patients With Non-diabetic Glomerulonephritis |
Renal Cell Carcinoma (Kidney Cancer) (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06818305 | EmFin-Nx | P2 | terminated | Efficacy and Safety of Finerenone and Empagliflozin in Delaying Renal Function Progression After Radical Nephrectomy in High-Risk CKD Patients: A Multicenter RCT |
Patients With Type 2 Diabetes (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06727409 | RAiSiN | P4 | recruiting | Use of Clinical-trials and Simulation Models to Estimate Cost-effectiveness of Non-steroidal Mineralocorticoid Antagonists, RASi and SGLT2i as Triple Therapy With Type 2 Diabetes and Chronic Kidney Disease |
Type 2 Diabetes Mellitus (T2DM) (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07026539 | FineCaRe | P4 | recruiting | Effect of Treatment With Finerenone on Cardio-Renal Target Organ Damage in Patients With Type 2 Diabetes. |
IgA Nephropathy (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06580288 | FIGHT | P3 | not yet recruiting | Effect of Finerenone in IgA Nephropathy |
Primary Membranous Nephropathy (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06573411 | — | P4 | recruiting | Efficacy and Safety of Finerenone in Patients With Primary Membranous Nephropathy |
Chronic Kidney Diseases (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06058585 | CAPTIVATE | P3 | recruiting | The Chronic Kidney Disease Adaptive Platform Trial Investigating Various Agents for Therapeutic Effect |
Diabetes Mellitus Type 2 With Proteinuria (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06094920 | Optimize@Home | P4 | completed | Treatment Optimization for Patients With Type 2 Diabetes Using Empagliflozin and Finerenone in a Remote Clinical Trial |
Cardiovascular Diseases (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06082063 | Steno1 | P3 | recruiting | Multifactorial Intervention to Reduce Cardiovascular Disease in Type 1 Diabetes |
Kidney Transplant; Complications (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06059664 | — | P2 | recruiting | The EFfect of FinErenone in Kidney TransplantiOn Recipients: The EFFEKTOR Study |
Type2diabetes (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06244758 | — | P3 | completed | Finerenone and Renal Oxidative Stress |
Type 2 Diabetes (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05887817 | FIVE-STAR | P4 | active not recruiting | Effects of Finerenone on Vascular Stiffness and Cardiorenal Biomarkers in T2D and CKD (FIVE-STAR) |
Heart Failure With Left Ventricular Ejection Fraction Greater Than or Equal to 40 Per Cent (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07116512 | — | P1 | completed | A Study to Compare How Much of the Study Treatment Finerenone Gets Into the Blood When the Same Amount is Taken in One and in Two Tablets of Different Strengths in Healthy Male Participants |
Finerenone (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06460987 | — | N/A | completed | Study of the Clinical Efficacy and Safety of Finerenone for the Treatment of IGA Nephropathy |
Non-diabetic Chronic Kidney Disease (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05047263 | FIND-CKD | P3 | completed | A Trial to Learn How Well Finerenone Works and How Safe it is in Adult Participants With Non-diabetic Chronic Kidney Disease |
Diabetic Nephropathies (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01874431 | ARTS-DN | P2 | completed | Safety and Efficacy of Different Oral Doses of BAY94-8862 in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Nephropathy |
Clinical Pharmacology (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01473108 | — | P1 | completed | Study to Investigate the Natriuretic Effects, Safety, Tolerability and Pharmacokinetics of BAY94-8862 |
Alport Syndrome (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02378805 | Alport-XXL | N/A | recruiting | Alport Therapy Registry - European Initiative Towards Delaying Renal Failure in Alport Syndrome |
Finerenone pivotal trial highlights (Phase 2/3/4)
Phase-2/3/4 studies with named acronyms — the registration-grade trials most cited in label discussions and Wikipedia.
| Acronym | NCT | Phase | Status | Indication | Enrollment | PubMed |
|---|---|---|---|---|---|---|
| FINE-REMODEL | NCT07442448 | P4 | enrolling by invitation | Heart Failure and Preserved Ejection Fraction | 40 | PMID 31696627 |
| RAPID-CKD | NCT07547878 | P4 | not yet recruiting | Chronic Kidney Disease | 64 | — |
| FACILITATE-HF | NCT07397650 | P4 | recruiting | Acute Heart Failure | 550 | — |
| CKD-bioMatch | NCT07239570 | P4 | recruiting | Chronic Kidney Disease(CKD) | 125 | — |
| FICHSPN | NCT07315191 | P4 | recruiting | Henoch Schönlein Purpura Nephritis | 116 | — |
| FineCaRe | NCT07026539 | P4 | recruiting | Type 2 Diabetes Mellitus (T2DM) | 80 | — |
| SIGNAL | NCT06954090 | P4 | enrolling by invitation | Type 2 DM | 50 | — |
| RAiSiN | NCT06727409 | P4 | recruiting | Patients With Type 2 Diabetes | 82 | — |
| SAFE-K | NCT07523867 | P4 | not yet recruiting | Heart Failure | 60 | — |
| FIN-SGLT2-HF | NCT07351864 | P4 | not yet recruiting | Heart Failure | 60 | PMID 38692445 |
| FIVE-STAR | NCT05887817 | P4 | active not recruiting | Type 2 Diabetes | 100 | PMID 37525257 |
| FAIRY | NCT06457074 | P4 | recruiting | Primary Aldosteronism | 306 | PMID 28699986 |
| Optimize@Home | NCT06094920 | P4 | completed | Diabetes Mellitus Type 2 With Proteinuria | 12 | — |
| FAVOR | NCT06164379 | P4 | unknown | Primary Aldosteronism | 150 | — |
| FINE-MECH | NCT07270367 | P3 | not yet recruiting | Heart Failure | 156 | PMID 37119065 |
| FIORELLO | NCT07192952 | P3 | recruiting | Left Ventricular Systolic Dysfunction | 117 | — |
| FIORE | NCT07188805 | P3 | recruiting | Left Ventricular Systolic Dysfunction | 111 | — |
| Steno1 | NCT06082063 | P3 | recruiting | Cardiovascular Diseases | 2,000 | PMID 39078403 |
| CAPTIVATE | NCT06058585 | P3 | recruiting | Chronic Kidney Diseases | 1,000 | PMID 39661388 |
| FIONA OLE | NCT05457283 | P3 | recruiting | Chronic Kidney Disease | 100 | — |
| FINALITY-HF | NCT06033950 | P3 | recruiting | Heart Failure | 2,600 | — |
| FINE-START | NCT07181135 | P3 | enrolling by invitation | Chronic Kidney Disease | 180 | — |
| REDEFINE-HF | NCT06008197 | P3 | recruiting | Heart Failure | 5,200 | — |
| FIONA | NCT05196035 | P3 | recruiting | Chronic Kidney Disease | 219 | PMID 38509517 |
| NEPHRON | NCT07223502 | P3 | recruiting | Hypertension (HTN) | 30 | — |
| FIGHT | NCT06580288 | P3 | not yet recruiting | IgA Nephropathy | 120 | — |
| CONFIRMATION | NCT06024746 | P3 | recruiting | Heart Failure | 1,500 | — |
| FIND-CKD | NCT05047263 | P3 | completed | Non-diabetic Chronic Kidney Disease | 1,584 | — |
| FINE-ONE | NCT05901831 | P3 | completed | Chronic Kidney Disease | 241 | PMID 40693871 |
| FINEARTS-HF | NCT04435626 | P3 | completed | Heart Failure | 6,016 | PMID 39217561 |
| FIGARO-DKD | NCT02545049 | P3 | completed | Diabetic Kidney Disease | 7,352 | PMID 31665733 |
| FIDELIO-DKD | NCT02540993 | P3 | completed | Chronic Kidney Disease | 5,734 | PMID 33198491 |
| FibroCAN | NCT06906081 | P2 | recruiting | Cardiovascular Autonomic Neuropathy | 100 | PMID 41130701 |
| EmFin-Nx | NCT06818305 | P2 | terminated | Renal Cell Carcinoma (Kidney Cancer) | 10 | — |
| CONFIDENCE | NCT05254002 | P2 | completed | Type 2 Diabetes Mellitus | 1,664 | PMID 39037799 |
| WP3 | NCT05897372 | P2 | terminated | Diabetic Kidney Disease | 1 | — |
| FIGARO-BM | NCT05013008 | P2 | completed | Chronic Kidney Disease | 951 | — |
| ARTS-HF | NCT01807221 | P2 | completed | Heart Failure | 1,066 | PMID 25678098 |
| ARTS-DN | NCT01874431 | P2 | completed | Diabetic Nephropathies | 823 | PMID 31583611 |
Terminated and withdrawn Finerenone trials (2)
Studies that ended before completion. Reasons are filed in each trial's ClinicalTrials.gov entry.
- NCT06818305terminatedEfficacy and Safety of Finerenone and Empagliflozin in Delaying Renal Function Progression After Radical Nephrectomy in High-Risk CKD Patients: A Multicenter RCT
- NCT05897372terminatedFeasibility of Aggressive Albuminuria Reduction in Biopsy-Proven Diabetic Nephropathy - a Pilot Study
All Finerenone trials (75)
Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.
| NCT ID | Acronym | Title | Phase | Status | Enrollment | Sponsor | Started |
|---|---|---|---|---|---|---|---|
| NCT02378805 | Alport-XXL | Alport Therapy Registry - European Initiative Towards Delaying Renal Failure in Alport Syndrome | — | recruiting | 800 | University Hospital Goettingen | Jul 1995 |
| NCT07270367 | FINE-MECH | Finerenone and Cardiac Remodeling | P3 | not yet recruiting | 156 | Subodh Verma | Dec 2025 |
| NCT07192952 | FIORELLO | A Study to Learn More About How Safe Finerenone is, When it is Taken for a Longer Time With Standard Treatment, in Children and Young Adults With Heart Failure and Left Ventricular Systolic Dysfunction | P3 | recruiting | 117 | Bayer | Jun 2026 |
| NCT07442448 | FINE-REMODEL | Investigation on the Impact of Finerenone on Myocardial Remodeling in Patients With Diabetic Kidney Disease and Heart Failure | P4 | enrolling by invitation | 40 | Cathay General Hospital | Apr 2026 |
| NCT07188805 | FIORE | A Study to Learn More About How Well Finerenone Works, How Safe it is, and How it Moves Into, Through, and Out of the Body Compared to Placebo When Taken With Standard Treatment in Children With Heart Failure and Left Ventricular Systolic Dysfunction | P3 | recruiting | 111 | Bayer | Nov 2025 |
| NCT06082063 | Steno1 | Multifactorial Intervention to Reduce Cardiovascular Disease in Type 1 Diabetes | P3 | recruiting | 2,000 | Steno Diabetes Center Copenhagen | Jul 2024 |
| NCT07554469 | FINEXPLORER | An Observational Study, Called FINEXPLORER, to Learn More About How Well Finerenone Works in Adults in Spain With Chronic Kidney Disease (CKD) Linked to Type 2 Diabetes, by Looking at Changes in a CKD Risk Score | — | not yet recruiting | 500 | Bayer | May 2026 |
| NCT07547878 | RAPID-CKD | Rapid and Simultaneous Initiation of Four Guideline-Directed CKD Therapies (RAPID-CKD) | P4 | not yet recruiting | 64 | Baylor Research Institute | Apr 2026 |
| NCT06058585 | CAPTIVATE | The Chronic Kidney Disease Adaptive Platform Trial Investigating Various Agents for Therapeutic Effect | P3 | recruiting | 1,000 | The George Institute | Sep 2024 |
| NCT05457283 | FIONA OLE | A Study to Learn More About How Safe the Study Treatment Finerenone is in Long-term Use When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker Over 18 Months of Use in Children and Young Adults From 1 to 18 Years of Age With Chronic Kidney Disease and Proteinuria | P3 | recruiting | 100 | Bayer | Nov 2022 |
| NCT07397650 | FACILITATE-HF | Efficacy and Safety With Early Treatment of Finerenone in Hospitalized Patients With Heart Failure | P4 | recruiting | 550 | Juntendo University | Feb 2026 |
| NCT07239570 | CKD-bioMatch | A Biomarker-targeted Clinical Trial to Optimize Treatment for Patients With Chronic Kidney Disease | P4 | recruiting | 125 | Peter Rossing | Jun 2025 |
| NCT07315191 | FICHSPN | Finerenone Therapy for Pediatric HSPN With Mild Proteinuria | P4 | recruiting | 116 | Capital Institute of Pediatrics, China | Jun 2025 |
| NCT07026539 | FineCaRe | Effect of Treatment With Finerenone on Cardio-Renal Target Organ Damage in Patients With Type 2 Diabetes. | P4 | recruiting | 80 | University of Aarhus | Oct 2024 |
| NCT06033950 | FINALITY-HF | A Study to Evaluate Finerenone on Clinical Efficacy and Safety in Patients with Heart Failure Who Are Intolerant or Not Eligible for Treatment with Steroidal Mineralocorticoid Receptor Antagonists | P3 | recruiting | 2,600 | Colorado Prevention Center | Aug 2024 |
| NCT06906081 | FibroCAN | Finerenone Treatment for Diabetic Cardiovascular Autonomic Neuropathy: the FibroCAN Study | P2 | recruiting | 100 | Peter Rossing | May 2025 |
| NCT07232537 | An Observational Study Called FINE-REAL Korea to Learn More About the Use of the Drug Finerenone in People With Chronic Kidney Disease and Type 2 Diabetes in a Routine Medical Care Setting in South Korea | — | recruiting | 500 | Bayer | Nov 2025 | |
| NCT07181135 | FINE-START | FINE-START: Efficacy and Safety of Finerenone in Patients With Chronic Kidney Disease Not Using Renin-angiotensin-system Inhibitors | P3 | enrolling by invitation | 180 | University Medical Center Groningen | Mar 2026 |
| NCT06059664 | The EFfect of FinErenone in Kidney TransplantiOn Recipients: The EFFEKTOR Study | P2 | recruiting | 100 | University of North Carolina, Chapel Hill | Apr 2024 | |
| NCT06008197 | REDEFINE-HF | A Study to Determine the Efficacy and Safety of Finerenone on Morbidity and Mortality Among Hospitalized Heart Failure Patients | P3 | recruiting | 5,200 | Colorado Prevention Center | Jan 2024 |
| NCT05348733 | A Study Called FINE-REAL to Learn More About the Use of the Drug Finerenone in a Routine Medical Care Setting | — | active not recruiting | 4,613 | Bayer | Jun 2022 | |
| NCT07379840 | A Study to Learn More About How Safe Finerenone is and How Well it Works in Adults With Chronic Heart Failure in South Korea | — | recruiting | 300 | Bayer | Dec 2025 | |
| NCT07155694 | Role of Finerenone in African American Veterans With Diabetic Kidney Disease | P4 | not yet recruiting | 30 | Washington D.C. Veterans Affairs Medical Center | Sep 2025 | |
| NCT05196035 | FIONA | A Study to Learn More About How Well the Study Treatment Finerenone Works, How Safe it is, How it Moves Into, Through, and Out of the Body, and the Effects it Has on the Body When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker in Children With Chronic Kidney Disease and Proteinuria | P3 | recruiting | 219 | Bayer | Mar 2022 |
| NCT07537088 | Efficacy and Safety of Triple Therapy With Dulaglutide, SGLT2 Inhibitors, and Finerenone in Chinese Adults With Type 2 Diabetes and Chronic Kidney Disease | P4 | not yet recruiting | 468 | First Affiliated Hospital of Wannan Medical College | May 2026 | |
| NCT06954090 | SIGNAL | Urinary Proteomics to Guide Early Intervention to Prevent Complications in Type 2 Diabetes - a Feasibility Study | P4 | enrolling by invitation | 50 | Steno Diabetes Center Copenhagen | Nov 2025 |
| NCT07235891 | Retinal Protective Effects of Novel Finerenone in Patients With Chronic Kidney Disease | P4 | not yet recruiting | 40 | Alexandria University | Nov 2025 | |
| NCT06727409 | RAiSiN | Use of Clinical-trials and Simulation Models to Estimate Cost-effectiveness of Non-steroidal Mineralocorticoid Antagonists, RASi and SGLT2i as Triple Therapy With Type 2 Diabetes and Chronic Kidney Disease | P4 | recruiting | 82 | Chinese University of Hong Kong | Dec 2024 |
| NCT06838416 | KSD-01 | Evaluation of the Effect of Finerenone on Renal Function in Patients With Type 2 Diabetes and Chronic Kidney Disease | — | recruiting | 300 | Second Affiliated Hospital of Soochow University | Nov 2023 |
| NCT07523867 | SAFE-K | Spironolactone Alternate Dosing vs Finerenone in Elevated Potassium - K Safety Study | P4 | not yet recruiting | 60 | Hospital de Messejana Dr. Carlos Alberto Studart Gomes | Apr 2026 |
| NCT07223502 | NEPHRON | A Study Comparing the Clinical Benefit of Finerenone Versus a Fixed Dose Combination (FDC) of Extended-Release Torsemide and Spironolactone in Patients With Hypertension and Chronic Kidney Disease | P3 | recruiting | 30 | Sarfez Pharmaceuticals, Inc. | Dec 2025 |
| NCT06573411 | Efficacy and Safety of Finerenone in Patients With Primary Membranous Nephropathy | P4 | recruiting | 116 | First Affiliated Hospital, Sun Yat-Sen University | Sep 2024 | |
| NCT06580288 | FIGHT | Effect of Finerenone in IgA Nephropathy | P3 | not yet recruiting | 120 | Zhejiang University | Oct 2024 |
| NCT06278207 | FINEROD | An Observational Study Called FINEROD to Learn More About the Use of the Treatment Finerenone Including How Safe it is and How Well it Works Under Real-world Conditions | — | recruiting | 50,000 | Bayer | May 2024 |
| NCT06024746 | CONFIRMATION | A Study to Determine the Efficacy and Safety of Finerenone and SGLT2i in Combination in Hospitalized Patients with Heart Failure (CONFIRMATION-HF) | P3 | recruiting | 1,500 | Colorado Prevention Center | Jul 2024 |
| NCT07351864 | FIN-SGLT2-HF | Finerenone Plus SGLT2 Inhibitors in Heart Failure | P4 | not yet recruiting | 60 | Mansoura University | Jan 2026 |
| NCT05887817 | FIVE-STAR | Effects of Finerenone on Vascular Stiffness and Cardiorenal Biomarkers in T2D and CKD (FIVE-STAR) | P4 | active not recruiting | 100 | Saga University | Sep 2023 |
| NCT07326631 | Finerenone for Cardiorenal Protection in Diabetic CKD: Impact on Renal Function Decline and Heart Failure | N/A | not yet recruiting | 120 | College of Physicians and Surgeons Pakistan | Jan 2026 | |
| NCT06763146 | IN-REALITY | An Observational Study to Learn More About How Safe Finerenone is and How Well it Works in Indian People With Chronic Kidney Disease and Type 2 Diabetes in Routine Medical Practice | — | active not recruiting | 1,200 | Bayer | Sep 2025 |
| NCT06608212 | An Observational Study to Learn More About How Safe Finerenone is and How Well it Works in People With Chronic Kidney Disease and Type 2 Diabetes in Routine Medical Care in the United States | — | active not recruiting | 150,000 | Bayer | Oct 2024 | |
| NCT06457074 | FAIRY | Finerenone for Patients With Primary Aldosteronism (FAIRY) | P4 | recruiting | 306 | Qifu Li | Jun 2024 |
| NCT07056595 | Finerenone in Patients With IgA-nephropathy: Prospective Interventional Trial | N/A | recruiting | 30 | Botkin Hospital | May 2025 | |
| NCT06835322 | Effect of Finerenone in Patients With Non-diabetic Glomerulonephritis | P2 | completed | 100 | Alexandria University | Apr 2025 | |
| NCT05814770 | Comparing the Efficacy and Safety of Finerenone and Spironolactone in the Treatment of Primary Aldosteronism | P4 | unknown | 96 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | May 2023 | |
| NCT07124039 | FIRST-2_CN | An Observational Study Called FIRST-2.0 China to Learn More About the Use of the Study Treatment Finerenone Including How Safe it is and How Well it Works Under Real-world Conditions in a Chinese Population. | — | completed | 6,537 | Bayer | Jul 2025 |
| NCT05047263 | FIND-CKD | A Trial to Learn How Well Finerenone Works and How Safe it is in Adult Participants With Non-diabetic Chronic Kidney Disease | P3 | completed | 1,584 | Bayer | Sep 2021 |
| NCT06244758 | Finerenone and Renal Oxidative Stress | P3 | completed | 91 | University of Erlangen-Nürnberg Medical School | Jan 2024 | |
| NCT05552339 | SMART-Finder | A Study Called SMART-Finder to Look for People With Increased Amounts of Albumin in the Urine (UACR Level) in a Group of Type 2 Diabetes Mellitus Patients | — | completed | 348 | Bayer | Aug 2023 |
| NCT06818305 | EmFin-Nx | Efficacy and Safety of Finerenone and Empagliflozin in Delaying Renal Function Progression After Radical Nephrectomy in High-Risk CKD Patients: A Multicenter RCT | P2 | terminated | 10 | Jinling Hospital, China | Jan 2025 |
| NCT06094920 | Optimize@Home | Treatment Optimization for Patients With Type 2 Diabetes Using Empagliflozin and Finerenone in a Remote Clinical Trial | P4 | completed | 12 | University Medical Center Groningen | Jul 2024 |
| NCT05901831 | FINE-ONE | A Study to Learn How Well the Study Treatment Finerenone Works and How Safe it is in People With Long-term Decrease in the Kidneys' Ability to Work Properly (Chronic Kidney Disease) Together With Type 1 Diabetes | P3 | completed | 241 | Bayer | Feb 2024 |
| NCT05705271 | A Study to Learn How Safe the Study Drug Finerenone is and How Well it Works in Indian People With Long-term Decrease in the Kidneys' Ability to Work Properly (Chronic Kidney Disease) Together With Type 2 Diabetes Mellitus | P4 | completed | 200 | Bayer | Feb 2023 | |
| NCT06381323 | The Clinical Efficacy and Safety of Finerenone in the Treatment of Primary Aldosteronism | P4 | completed | 55 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Mar 2024 | |
| NCT05254002 | CONFIDENCE | A Study to Learn How Well the Treatment Combination of Finerenone and Empagliflozin Works and How Safe it is Compared to Each Treatment Alone in Adult Participants With Long-term Kidney Disease (Chronic Kidney Disease) and Type 2 Diabetes | P2 | completed | 1,664 | Bayer | Jun 2022 |
| NCT06164379 | FAVOR | Efficacy and Safety of Finerenone vs. Spironolactone in Patients With Primary Aldosteronism | P4 | unknown | 150 | Shanghai Jiao Tong University School of Medicine | Dec 2023 |
| NCT05703880 | FIRST-2 | An Observational Study Called FIRST-2.0 to Learn More About the Use of the Study Treatment Finerenone Including How Safe it is and How Well it Works Under Real-world Conditions | — | completed | 15,948 | Bayer | Jun 2023 |
| NCT05897372 | WP3 | Feasibility of Aggressive Albuminuria Reduction in Biopsy-Proven Diabetic Nephropathy - a Pilot Study | P2 | terminated | 1 | Iain Bressendorff | Aug 2023 |
| NCT05526157 | FINEGUST | An Observational Study, Called FINEGUST, to Learn More About How People With Chronic Kidney Disease and Type 2 Diabetes Are Treated and How the Introduction of New Treatment Options, Like Finerenone, Impacts Clinical Practice | — | completed | 50,000 | Bayer | Oct 2022 |
| NCT04435626 | FINEARTS-HF | Study to Evaluate the Efficacy (Effect on Disease) and Safety of Finerenone in Participants With Heart Failure and Left Ventricular Ejection Fraction (Proportion of Blood Expelled Per Heart Stroke) Greater or Equal to 40% | P3 | completed | 6,016 | Bayer | Sep 2020 |
| NCT06460987 | Study of the Clinical Efficacy and Safety of Finerenone for the Treatment of IGA Nephropathy | — | completed | 245 | The Fourth Affiliated Hospital of Zhejiang University School of Medicine | Dec 2022 | |
| NCT05924620 | Efficacy and Safety of Finerenone in Patients With Primary Aldosteronism | P4 | completed | 60 | Chongqing Medical University | Jun 2023 | |
| NCT05640180 | FLAMINGO | An Observational Study Called FLAMINgO to Learn More About the Treatment Combination of Finerenone and SGLT2 Inhibitors in People With Long-term Kidney Disease (Chronic Kidney Disease) Together With Type 2 Diabetes by Using Routine Medical Care Data and Past Clinical Study Results | — | completed | 17,847 | Bayer | Nov 2022 |
| NCT07116512 | A Study to Compare How Much of the Study Treatment Finerenone Gets Into the Blood When the Same Amount is Taken in One and in Two Tablets of Different Strengths in Healthy Male Participants | P1 | completed | 60 | Bayer | May 2023 | |
| NCT05013008 | FIGARO-BM | An add-on Study to the FIGARO-DKD Study Called FIGARO-BM to Learn About the Link Between Biomarkers (Substances in the Blood Used as Indicators of Biological Processes, Disease Processes or Responses to Medication) and Finerenone in FIGARO-DKD Participants | P2 | completed | 951 | Bayer | Aug 2021 |
| NCT04795726 | DeFineDR | A Study That Uses Data From Routine Eye Examinations of Patients Participating in Studies FIDELIO-DKD and FIGARO-DKD to Explore Whether Finerenone Can Delay the Progression of a Diabetes Complication That Affects the Eyes (Diabetic Retinopathy, DR) | N/A | completed | 70 | Bayer | Mar 2021 |
| NCT04477707 | ReFineDR | A Study That Uses Data From Routine Eye Examinations of Patients Participating in Studies FIDELIO-DKD and FIGARO-DKD to Explore Whether Finerenone Can Delay the Progression of a Diabetes Complication That Affects the Eyes (Diabetic Retinopathy ,DR) | — | completed | 206 | Bayer | Jul 2020 |
| NCT02545049 | FIGARO-DKD | Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Kidney Disease | P3 | completed | 7,352 | Bayer | Sep 2015 |
| NCT02540993 | FIDELIO-DKD | Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and Diabetic Kidney Disease | P3 | completed | 5,734 | Bayer | Sep 2015 |
| NCT02956109 | Study of Finerenone to Investigate a Paediatric Formulation in Healthy Male Volunteers | P1 | completed | 16 | Bayer | Nov 2016 | |
| NCT02957396 | Study of Finerenone to Investigate a Paediatric Formulation in Healthy Male Subjects | P1 | completed | 16 | Bayer | Nov 2016 | |
| NCT01807221 | ARTS-HF | Phase IIb Safety and Efficacy Study of Different Oral Doses of BAY94-8862 in Subjects With Worsening Chronic Heart Failure and Left Ventricular Systolic Dysfunction and Either Type 2 Diabetes Mellitus With or Without Chronic Kidney Disease or Chronic Kidney Disease Alone | P2 | completed | 1,066 | Bayer | Jun 2013 |
| NCT04881994 | BAY94-8862 | A Study to Learn How Finerenone (BAY94-8862) Moves Into, Through and Out of the Body, How it Affects the Body, and How Safe it is in Adult Participants With Different Degrees of Reduced Liver Function and in Healthy Participants With Similar Age, Weight and Gender Distribution | P1 | completed | 27 | Bayer | Mar 2014 |
| NCT01874431 | ARTS-DN | Safety and Efficacy of Different Oral Doses of BAY94-8862 in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Nephropathy | P2 | completed | 823 | Bayer | Jun 2013 |
| NCT04908436 | A Study to Learn How BAY94-8862 Moves Into, Through and Out of the Body, How Safe it is and How it Affects the Body in Adult Participants With Reduced Kidney Function and in Healthy Participants With Similar Age, Weight and Gender Distribution | P1 | completed | 33 | Bayer | Oct 2010 | |
| NCT01473108 | Study to Investigate the Natriuretic Effects, Safety, Tolerability and Pharmacokinetics of BAY94-8862 | P1 | completed | 67 | Bayer | Mar 2010 |
Finerenone clinical trials: frequently asked questions
- How many Finerenone clinical trials are there?
- 75 Finerenone clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 28 are actively recruiting participants. 29 are marked completed.
- Are Finerenone clinical trials recruiting in 2026?
- Yes — 28 Finerenone trials are actively recruiting in 2026, with 102 U.S. sites across 33 states. See the recruiting trials and the per-state site list further down this page.
- What conditions is Finerenone being studied for?
- Finerenone is being studied for Chronic Kidney Disease, Type 2 Diabetes Mellitus, Heart Failure, Primary Aldosteronism, Diabetic Kidney Disease and 68 more. The trials are grouped by indication on this page.
- What phase is Finerenone in?
- Finerenone clinical trials span 22 Phase 4, 19 Phase 3, 9 Phase 2, 6 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
- Who sponsors Finerenone clinical trials?
- The lead sponsor across the most Finerenone trials is Bayer, with 34 additional lead sponsors listed in the data. Each trial row links to the full study detail page including sponsor information.
Sources and methodology
Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming Finerenoneas an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.
Last refreshed .
Related pages on Hipa.ai: